Rich Pharmaceuticals, Inc. Stock Price - RCHA

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Small Cap Pro
Monthly Subscription
for only
$49.05
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Rich Pharmaceuticals, Inc. RCHA Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 0.0001 0.00 0.00 0.00 0.0001 20:00:00
Bid Price Ask Price Spread Spread % News
0.0001 0.0002 0.00 0.00% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Rich Pharmaceuticals, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 207.19k 2.07B $ -1.69M - -0.12 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
21.00k $ - 0.00% - -

more financials information »

Rich Pharmaceuticals, Inc. News

Latest RCHA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RCHA Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.00010.00010.00010.00011M0-
1 Month0.00010.00020.00010.00014M0-
3 Months0.00010.00020.00010.00013M0-
6 Months0.00020.00020.00010.00013M-0.0001-50.00%
1 Year0.00020.00030.00010.00024M-0.0001-50.00%
3 Years0.00010.00780.000010.000629M0-
5 Years0.06010.070.0000010.000835M-0.06-99.83%

Rich Pharmaceuticals, Inc. Description

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, TPA (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in this and possibly other indications is the result of the work of Prof. Richard Chang. He has conducted research on TPA for many years and has become an expert in the characteristics of this molecule. The findings form the scientific basis for the clinical use of TPA.


Your Recent History
USOTC
RCHA
Rich Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.